Is CHGCF or NOBL a better dividend investment in 2026?

CHGCF currently yields 2.90% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: CHGCF offers higher current income.

What is the dividend yield difference between CHGCF and NOBL?

CHGCF has a forward dividend yield of 2.90% ($1.62/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 0.73 percentage points.

Home › Compare › CHGCF vs NOBL

CHGCF vs NOBL: Dividend Comparison 2026

CHGCF yields 2.90% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CHGCF wins by $350.25M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CHGCF

● Live price

2.90%

Share price

$55.78

Annual div

$1.62

5Y div CAGR

100%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$350.27M

Annual income

$328,490,171.71

Full CHGCF calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — CHGCF vs NOBL

📍 CHGCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CHGCF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CHGCF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CHGCF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCF

Annual income on $10K today (after 15% tax)

$246.26/yr

After 10yr DRIP, annual income (after tax)

$279,216,645.95/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, CHGCF beats the other by $279,216,433.64/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCF + NOBL for your $10,000?

CHGCF: 50%NOBL: 50%

100% NOBL50/50100% CHGCF

Portfolio after 10yr

$175.15M

Annual income

$164,245,210.74/yr

Blended yield

93.78%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCF buys

NOBL buys

No recent congressional trades found for CHGCF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCHGCFNOBL

Forward yield	2.90% ✓	2.17%
Annual dividend / share	$1.62	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	100% ✓	0%
Portfolio after 10y	$350.27M ✓	$22.9K
Annual income after 10y	$328,490,171.71 ✓	$249.78
Total dividends collected	$348.65M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CHGCF vs NOBL ($10,000, DRIP)

Year	CHGCF Portfolio	CHGCF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$11,279	$579.45	$10,917	$217.08	+$362.00 → CHGCF
2	$13,291	$1,221.65	$11,903	$221.48	+$1.4K → CHGCF
3	$16,912	$2,690.62	$12,962	$225.68	+$4.0K → CHGCF
4	$24,495	$6,399.38	$14,099	$229.68	+$10.4K → CHGCF
5	$43,534	$17,324.98	$15,319	$233.49	+$28.2K → CHGCF
6	$104,136	$57,554.30	$16,628	$237.10	+$87.5K → CHGCF
7	$368,757	$257,331.25	$18,033	$240.53	+$350.7K → CHGCF
8	$2,097,816	$1,703,246.11	$19,539	$243.78	+$2.08M → CHGCF
9	$20,356,014	$18,111,350.35	$21,154	$246.86	+$20.33M → CHGCF
10	$350,271,106	$328,490,171.71	$22,884	$249.78	+$350.25M → CHGCF

CHGCF vs NOBL: Complete Analysis 2026

CHGCF — Stock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this CHGCF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCF vs SCHD CHGCF vs JEPI CHGCF vs O CHGCF vs KO CHGCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.